Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Renjie JinConnor M ForbesNicole L MillerDouglas W StrandThomas CaseJustin Merrill Marken CatesHye-Young H KimPhillip A WagesNed A PorterKrystin M MantioneSarah BurkeJames L MohlerRobert J MatusikPublished in: The Prostate (2022)
After failure of medical therapy for BPH/LUTS, 5ARI therapy continued to inhibit androgenesis but a 5ARI-induced pathway increased tissue levels of GC not seen in patients on α-blockers. GC stimulation of organoids indicated that the GC receptors are a trigger for controlling growth of prostate glands. A 5ARI-induced pathway revealed GC activation can serve as a master regulator of prostatic branching and growth.
Keyphrases
- end stage renal disease
- benign prostatic hyperplasia
- newly diagnosed
- prostate cancer
- high glucose
- chronic kidney disease
- ejection fraction
- diabetic rats
- endothelial cells
- prognostic factors
- healthcare
- peritoneal dialysis
- drug induced
- oxidative stress
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- radical prostatectomy
- bone marrow
- high resolution
- patient reported
- tandem mass spectrometry